All In Biotech

NDA 015296 · Eurofarma

Synalar

Fluocinolone Acetonide · Topical

Last checked: Nov 19, 2026Latest source record: Nov 19, 2012 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1964

May 27, 1964

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

20 Phase 3, 7 recruiting

FAERS reports

1,919

865 serious, 53 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 27, 1964 Original approval · Type 3 - New Dosage Form
1 products under this application
  • SYNALAR · FLUOCINOLONE ACETONIDE 0.01% · SOLUTION, TOPICAL · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluocinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pruritus191
  • drug ineffective182
  • rash152
  • diarrhoea120
  • off label use113
  • fatigue103
  • psoriasis102
  • headache97
  • pain97
  • nausea88
  • dermatitis atopic81
  • product use in unapproved indication78

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
200518
20067
200713
200811
200918
201020
201132
201234
201328
201430
201559
201693
201785
201895
2019130
2020137
2021139
2022168
2023194
2024185
2025223
2026191

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 142 on PubMed

Sponsor: Eurofarma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.